Shareholder uprising against PPD merger quelled by settlement
But not all investors are happy with agreement which allows $3.9 billion deal to proceed
Despite objections from one institutional shareholder, the North Carolina Business Court has approved the settlement of a class action against Wilmington-based clinical research company Pharmaceutical Product Development Inc. and two private equity firms.Login required
You have clicked on a link to
information that is | ||
Already a paid subscriber but not registered for online access yet? For instructions on how to get premium web access, click here. |
||
Interested in Subscribing?
Start by choosing how you'd like your news delivered.
![]() - Print and Digital - | ![]() - Digital Only - |
![]() Try North Carolina Lawyers Weekly for a month |
Published: June 15, 2012
Time posted: 4:47 pm






![[Print]](http://nclawyersweekly.com/wp-content/plugins/tdc-sociable-toolbar/print.png)
![[Email]](http://nclawyersweekly.com/wp-content/plugins/tdc-sociable-toolbar/email_2.png)
![[RSS Feed]](http://nclawyersweekly.com/wp-content/plugins/tdc-sociable-toolbar/rssfeed.png)
![[Facebook]](http://nclawyersweekly.com/wp-content/plugins/tdc-sociable-toolbar/facebook.png)
![[Twitter]](http://nclawyersweekly.com/wp-content/plugins/tdc-sociable-toolbar/twitter.png)



